JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)

Contributed by: Business Wire

Logo

Tags

Biotechnology

General Health

Health

Pharmaceutical

Clinical Trials

JJP Biologics

More Like This

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023

PR Newswire associated0

ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Fermion's TYK2 JH2 Inhibitor FZ007-119 Granted IND Approval by China NMPA

Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487

PR Newswire associated0

Phase I Study Results for Qilu Pharmaceutical's Iparomlimab (QL1604) Now Published

Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology

Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial